GC Biopharma녹십자
006280 · KOSPI · ₩006280 · 녹십자
₩132,000▲ ₩1,500 (1.15%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩2T | ₩1.7T | ₩1.6T | ₩1.7T | ₩1.5T |
| Cost of sales | ₩1.4T | ₩1.2T | ₩1.1T | ₩1.1T | ₩1T |
| Gross profit | ₩554B | ₩482B | ₩485B | ₩582B | ₩521B |
| Operating income | ₩69B | ₩32B | ₩34B | ₩81B | ₩74B |
| Net income | −₩30B | −₩43B | −₩20B | ₩69B | ₩137B |
| Net income to shareholders | −₩4.7B | −₩26B | −₩27B | ₩65B | ₩123B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩3T | ₩2.7T | ₩2.6T | ₩2.5T | ₩2.5T |
| Current assets | ₩1.4T | ₩1.2T | ₩1T | ₩980B | ₩1.1T |
| Cash and equivalents | ₩49B | ₩23B | ₩50B | ₩105B | ₩186B |
| Total liabilities | ₩1.6T | ₩1.3T | ₩1.1T | ₩959B | ₩962B |
| Current liabilities | ₩1.1T | ₩769B | ₩869B | ₩541B | ₩553B |
| Borrowings | ₩862B | ₩717B | ₩85B | ₩279B | ₩280B |
| Total equity | ₩1.4T | ₩1.5T | ₩1.5T | ₩1.6T | ₩1.5T |
| Shareholders' equity | ₩1.2T | ₩1.3T | ₩1.3T | ₩1.3T | ₩1.3T |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩99B | −₩53B | −₩5.5B | ₩119B | ₩126B |
| Capital spending | ₩72B | ₩32B | ₩79B | ₩58B | ₩102B |
| Free cash flow | ₩27B | −₩85B | −₩85B | ₩61B | ₩24B |
| Dividends paid | ₩19B | ₩20B | ₩25B | ₩24B | ₩19B |
Consolidated where available. Amounts in won.
Also known as: GC Biopharma / 녹십자 / 006280 / KRX:006280
Source: KRX statistical information